Adaptive licensing: will national agencies stop Rasi and the EMA?
This article was originally published in Scrip
The European Commission and German health technology assessors have poured cold water on aspirations by European Medicines Agency head Guido Rasi to introduce an adaptive licensing approach for evaluating and approving medicines.
You may also be interested in...
An advanced immunotherapy for recurrent glioblastoma and the first biosimilar version of Lucentis for age-related macular degeneration have also been submitted for review by the European Medicines Agency for potential pan-EU authorization.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.
Novartis’s siRNA for lowering cholesterol was also among the 10 new medicines that the European Medicines Agency this week said should be approved in the EU.